Clinical Trials Logo

Primary Mitochondrial Myopathy clinical trials

View clinical trials related to Primary Mitochondrial Myopathy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05267574 Terminated - Clinical trials for Primary Mitochondrial Myopathy

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Start date: February 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to evaluate the long-term safety and tolerability of REN001 administered once daily to subjects with PMM due to mitochondrial DNA mutations (mtDNA-PMM) or nuclear DNA mutations (nDNA-PMM). Subjects with mtDNA mutations will have previously completed Study REN001-201 or participated in Study REN001-101. Subjects with nDNA mutations who enroll in this study will be REN001- naïve.

NCT ID: NCT04641962 Terminated - Clinical trials for Primary Mitochondrial Myopathy

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

MOUNTAINSIDE
Start date: May 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dose response of ASP0367 on functional improvement relative to placebo, safety, and tolerability in participants with Primary Mitochondrial Myopathy.

NCT ID: NCT03862846 Terminated - Clinical trials for Primary Mitochondrial Myopathy

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Start date: May 10, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy

NCT ID: NCT03323749 Terminated - Clinical trials for Primary Mitochondrial Myopathy

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

MMPOWER-3
Start date: October 9, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety and efficacy of daily subcutaneous injections of elamipretide in subjects with primary mitochondrial myopathy. This will be followed by an open-label treatment extension.